Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US9229671048
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00Z1S1G39
MANE
Veradermics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: -
NAME
Veradermics, Inc.
ISIN
US9229671048
TICKER
MANE
MIC
XNYS
REUTERS
MANE.N
BLOOMBERG
MANE US
So., 26.04.2026       Veradermics
US9229671048

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302’ clinical...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Veradermics
US9229671048

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today reported financial results for the fourth quarter and full year periods ended December 31, 2025, and announced recent corporate and cl...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Veradermics
US9229671048

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Veradermics
US9229671048

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthc...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.02.2026       Veradermics
US9229671048

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Veradermics
US9229671048

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common s...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.02.2026       Veradermics
US9229671048

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial pu...
Zur Nachricht
Veradermics
Charts & Research Termsheets Terminal
Permalink